Background The first licensed malaria vaccine, RTS, S/AS01 E, confers moderate protection
against symptomatic disease. Because many malaria infections are asymptomatic, we …

Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

Summary Background The RTS, S/AS01 E malaria vaccine (RTS, S) was introduced by
national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale …

Background The target delivery channel of RTS, S candidate malaria vaccines in malaria-
endemic countries in Africa is the World Health Organisation Expanded Program on …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The development of a malaria vaccine remains a public health priority for sub‐
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …

The malaria vaccine candidate, RTS, S/AS01E, showed promising protective efficacy in a
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …